Should Older Women Keep Getting Breast Cancer Screenings?

After 75, the mammogram question often stops feeling routine. One woman is told, “The evidence is insufficient.” Another hears, “Keep going if you’re healthy.” A third is told there is “no upper age limit.” Those are not the same instruction, and they leave too many older women trying to turn a guideline into a personal decision while sitting in an exam room with a paper gown on.

The plain answer is this: age alone does not decide whether an older woman should keep getting breast cancer screening. U.S. organizations disagree most sharply after age 75, not because breast cancer stops mattering, but because the evidence about screening benefit becomes less certain while the chance of harm from overdiagnosis, follow-up testing, and treatment burden becomes more important.

This guide is for general education and is not medical advice. It should be used to prepare for a conversation with a clinician who knows the woman’s health history, breast cancer risk, medications, functional status, and preferences. Guideline and Medicare details in this article were last verified August 25, 2026; because recommendations and coverage can change, confirm current guidance with a clinician or Medicare.

Why the answer changes after 75

For average-risk women, the U.S. Preventive Services Task Force recommends mammography every 2 years from ages 40 through 74. At age 75 and older, the USPSTF gives an “I statement,” meaning the current evidence is insufficient to assess the balance of benefits and harms of screening in that age group. The Task Force also notes that no randomized clinical trial of breast cancer screening included women age 75 or older, which is a major reason the evidence thins out at exactly the age when many women want a clear answer. [1]

That “insufficient evidence” statement is often misunderstood. It is not the same as “stop screening at 75.” It means the USPSTF did not find enough direct trial evidence to make a population-wide recommendation for or against routine screening after 75. A woman who reads that as a stop sign may stop earlier than she would have chosen; a clinician who ignores it may continue ordering mammograms by habit. Neither response is much of a decision.

The American Cancer Society’s wording is practical because it asks whether a woman is in good overall health and has an expected life span of at least 10 more years. That does not mean anyone can predict an individual woman’s future perfectly. It means the possible benefit of screening usually takes time to show up, while the burdens of a callback, biopsy, diagnosis, or treatment can arrive almost immediately. [2]

The disagreement among organizations is not a scandal; it is the result of looking at incomplete evidence through different lenses. One group is stricter about population-level trial evidence. Another gives more weight to offering screening to healthy older women who may live many more years. Another emphasizes shared decision-making. The woman in the chair still needs one decision for her body and her life.

Breast cancer still matters in older women

Stopping routine screening is not the same as saying breast cancer is no longer a threat. Breast cancer incidence peaks around ages 70 to 74, and the National Cancer Institute estimates that a 70-year-old woman has about a 4% chance — about 1 in 24 — of being diagnosed with breast cancer over the next 10 years. [3]

Mortality is also not a younger woman’s issue only. AARP, citing American Cancer Society data, reports that more than half of breast cancer deaths occur in women age 70 and older. [4]

Those facts are why a dismissive “you’re too old to worry about it” answer is unacceptable. At the same time, seriousness alone does not prove that screening helps every woman in her late 70s, 80s, or beyond. The right question is narrower: is this particular woman likely to benefit from finding an early breast cancer by mammogram, and is she willing and able to go through the next steps if something is found?

What the benefit-and-harm evidence suggests

Because women 75 and older were not included in screening randomized trials, researchers have used other methods to estimate what may happen when older women continue or stop mammography. One useful trial emulation by García-Albéniz and colleagues, summarized by the USPSTF, found that continuing screening from ages 70 to 74 was associated with a 22% decrease in breast cancer mortality risk compared with stopping at age 70. The same analysis did not observe a mortality benefit from continued screening among women ages 75 to 79 or 80 to 84. [1]

That finding should be handled carefully. It does not prove that no woman over 75 can benefit. It does say the measurable population benefit becomes harder to demonstrate after 75, even while individual women vary widely in health, life expectancy, and breast cancer risk.

The harm side is not theoretical. A 2023 Annals of Internal Medicine study, reported by the National Cancer Institute, estimated that about 31% of screen-detected breast cancers in women ages 70 to 74 were overdiagnosed. The estimate rose to about 47% for women ages 75 to 84, and it exceeded 50% for some women with a life expectancy under 5 years. [5]

Overdiagnosis means a cancer is found that would not have caused symptoms or death during the woman’s remaining lifetime. No clinician can look at a single cancer on the day of diagnosis and know with certainty that it is overdiagnosed. That is what makes it so hard. A screen-detected cancer may lead to more imaging, biopsy, surgery, radiation, hormone therapy, or years of follow-up. For one woman, that treatment may be lifesaving. For another, it may take time, comfort, independence, or peace without adding meaningful length or quality to life.

The decision is not simply “screen” or “don’t screen”

A useful appointment does not begin and end with “I’m 78.” It should move from age to health status, risk, likely follow-through, and values. If the conversation is rushed, the woman or caregiver may need to slow it down with direct questions.

Start with overall health, not the calendar

A vigorous 78-year-old who walks daily, manages her chronic conditions well, lives independently, and would want treatment for an early breast cancer is not in the same situation as an 82-year-old with advanced heart failure, worsening dementia, repeated hospitalizations, or frailty that makes tests and treatment difficult. They may be the same “older age” on a chart, but the screening decision is not the same.

• Ask: “Given my overall health, am I likely to live long enough to benefit from finding a breast cancer early?”
• Ask: “Are any of my other medical conditions more likely to affect my life expectancy or quality of life than breast cancer?”
• Ask: “If my mammogram is abnormal, would I be healthy enough to go through diagnostic imaging, biopsy, and treatment if needed?”

Make life expectancy a medical estimate, not a polite guess

The ACS uses a 10-year life expectancy frame for continuing screening while overall health is good. That can feel uncomfortable to say out loud, but it is more respectful than pretending the question does not exist. The point is not to predict a date. The point is to ask whether the possible future benefit of screening is likely to arrive during the woman’s lifetime. [2]

Clinicians can use validated tools, geriatric assessment, and knowledge of the patient’s conditions to talk about this more honestly than family members usually can. An adult child may want certainty; the older woman needs a decision that fits her likely future.

Put personal breast cancer risk on the table

Average-risk guidance is not the same as guidance for every woman. A personal history of breast cancer, certain high-risk breast lesions, a strong family history, known genetic risk, prior chest radiation, or other risk factors can change the conversation. So can dense breasts, although evidence about supplemental screening after 75 is also limited.

The appointment should include one plain question: “Am I average risk, or is there something in my history that makes screening more important for me than for most women my age?” If the answer is not clear, the clinician should explain what information is missing.

Decide in advance what an abnormal result would mean

A screening mammogram is not a stand-alone event. It can lead to a callback, diagnostic mammogram, ultrasound, biopsy, surgical consultation, and treatment decisions. Before continuing screening, an older woman deserves to know what would likely happen if the result is abnormal.

• “If this mammogram shows something suspicious, what would the next test be?”
• “Would a biopsy be reasonable for me, given my health?”
• “If cancer were found, what treatment options would I realistically be offered?”
• “Could treatment be adjusted because of my age, other illnesses, or priorities?”
• “If I already know I would not want surgery, radiation, or medication, does screening still make sense?”

That last question is uncomfortable, but it is necessary. Screening is most coherent when a woman would consider doing something with the information. Some women want to know even if they might decline treatment. Others do not want a test that could start a chain of procedures they would not choose. Both positions deserve a clear conversation, not a lecture.

Name the values that matter most

Some women feel calmer continuing mammograms because they have always valued early detection. Some are willing to accept callbacks and biopsies for even a small chance of avoiding death from breast cancer. Others have lived through years of medical appointments and do not want more testing unless they have a symptom. Some fear treatment more than cancer. Some fear regret more than testing.

Values are not decorations added after the “real” medical decision. They are part of the decision. A woman who says, “I want to keep screening as long as I’m healthy enough to treat what we find,” is giving her clinician useful information. So is a woman who says, “At this stage, I do not want to look for a cancer that may never bother me.”

What about women ages 65 to 74?

The sharpest guideline uncertainty begins at 75, but women in their late 60s and early 70s still deserve more than automatic scheduling. The USPSTF recommends screening every 2 years through age 74, and the ACS allows women 55 and older to move to every 2 years or continue yearly screening. [1][2]

For many women 65 to 74, especially those in good health, screening remains a routine preventive service. Still, the same questions about health, risk, and willingness to act on abnormal results are worth asking before the decision becomes habit.

Medicare coverage: the practical part

Medicare Part B covers screening mammograms once every 12 months for eligible women, and there is no cost when the provider accepts assignment. Diagnostic mammograms are handled differently: Medicare states that patients pay 20% of the Medicare-approved amount after meeting the Part B deductible. These coverage details were last verified August 25, 2026. [6]

That difference matters because an abnormal screening result may lead to diagnostic imaging, and diagnostic testing may bring out-of-pocket costs. A woman should not have to discover that only after a callback.

Symptoms to report, whether or not screening continues

Screening status never replaces symptom awareness. A woman who stops routine mammograms should still report new breast changes promptly. A woman who keeps screening should do the same, even if her last mammogram was normal.

The CDC warning signs of breast cancer include: [7]

• Call a clinician for a new lump in the breast or underarm.
• Call for thickening, swelling, dimpling, irritation, redness, or flaky skin.
• Call for a nipple that turns inward, new nipple pain, or discharge that is not breast milk, including blood.
• Call for a new change in breast size or shape.
• Call for pain in any area of the breast or any breast change that is new or unusual for you.

Most breast changes are not breast cancer, but an older woman should not be reassured by age alone, and she should not wait for the next scheduled mammogram to mention a change. Symptoms need diagnostic attention, not routine screening.

A better appointment script

The shortest useful version of the conversation sounds something like this:

1. “I know guidelines differ after 75. Which guideline are you using for me, and why?”
2. “Based on my health, do you think I’m likely to live long enough to benefit from screening?”
3. “Am I average risk for breast cancer, or do I have risk factors that change the decision?”
4. “What are the chances this leads to more testing or treatment that may not help me?”
5. “If a cancer is found, what treatment would realistically be recommended for someone with my health?”
6. “If I choose to stop routine screening, what breast changes should I report right away?”

For some older women, especially those in good health with a longer life expectancy and a strong preference for early detection, continuing mammograms after 75 can be reasonable. For others, stopping can also be reasonable when limited life expectancy, frailty, other serious illness, treatment burden, or personal values make the likely harms outweigh the possible benefit.

The decision should be revisited if health changes. Guidelines should also be re-checked, because recommendations may change as new evidence appears. And no matter what a woman decides about routine screening, a new or unusual breast change deserves a prompt call to a clinician.

References

1. Breast Cancer: Screening — U.S. Preventive Services Task Force, April 30, 2024.
2. American Cancer Society Recommendations for the Early Detection of Breast Cancer — American Cancer Society.
3. Breast Cancer Risk in American Women — National Cancer Institute.
4. How Old Is Too Old for a Mammogram? — AARP.
5. Older Women, Screening Mammography, and Cancer Overdiagnosis — National Cancer Institute, 2023.
6. Mammograms — Medicare.gov.
7. Symptoms of Breast Cancer — Centers for Disease Control and Prevention.